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Background. Despite a typically good response to first-line combination chemotherapy, the prognosis for patients with advanced
ovarian cancer remains poor because of acquired chemoresistance. The use of targeted therapies such as trastuzumab may
potentially improve outcomes for patients with ovarian cancer. HER2 overexpression/amplification has been reported in ovarian
cancer, but the exact percentage of HER2-positive tumors varies widely in the literature. In this study, HER2 gene status was
evaluated in a large, multicentric series of 320 patients with advanced ovarian cancer, including 243 patients enrolled in
a multicenter prospective clinical trial of paclitaxel/carboplatin-based chemotherapy. Methodology/Principal Findings. The
HER2 status of primary tumors and metastases was evaluated by both immunohistochemistry (IHC) and fluorescence in situ
hybridization (FISH) analysis of paraffin-embedded tissue on conventional slides. The prognostic impact of HER2 expression was
analyzed. HER2 gene was overexpressed and amplified in 6.6% of analyzed tumors. Despite frequent intratumoral heterogeneity,
no statistically significant difference was detected between primary tumors and corresponding metastases. Conclusions/
Significance. Our results show that the decision algorithm usually used in breast cancer (IHC as a screening test, with equivocal
results confirmed by FISH) is appropriate in ovarian cancer. In contrast to previous series, HER2-positive status did not influence
outcome in the present study, possibly due to the fact that patients in our study received paclitaxel/carboplatin-based
chemotherapy. This raises the question of whether HER2 status and paclitaxel sensitively are linked.
Citation: Tuefferd M, Couturier J, Penault-Llorca F, Vincent-Salomon A, Broe ¨t P, et al (2007) HER2 Status in Ovarian Carcinomas: A Multicenter GINECO
Study of 320 Patients. PLoS ONE 2(11): e1138. doi:10.1371/journal.pone.0001138
INTRODUCTION
Because symptoms are usually absent, 70 to 80% of patients with
ovarian cancer will have advanced disease at the time of diagnosis
[1]. Despite an initial good response to first-line combination
chemotherapy (taxane/platinum), relapses are frequent because of
acquired chemoresistance. The use of new targeted therapies that
are potentially effective in a subset of patients may be of great value.
HER2 (human epidermal growth factor receptor-2) proto-
oncogene encodes a protein belonging to the EGFR tyrosine kinase
receptor family. Overexpression of HER2 initiates intracellular
signaling pathways involved in cell proliferation, differentiation,
migration and apoptosis [2]. In breast cancer, HER2-positive status
is associated with a poor prognosis [3], and also identifies patients
who could benefit from anthracycline-based regimens [4].
Trastuzumab (HerceptinH, F. Hoffmann-La Roche, Basel,
Switzerland) is a humanized monoclonal antibody that targets
the HER2 extracellular domain and inhibits HER2-positive tumor
cell proliferation. It is effective alone and in combination with
chemotherapy in patients with breast cancer whose tumors express
high levels of HER2 protein. The benefits of trastuzumab have
been demonstrated in both metastatic and adjuvant treatment
settings [5–8].
Accurate evaluation of HER2 status is essential for optimal
patient selection for trastuzumab. Among the numerous methods
published, immunohistochemistry (IHC) and fluorescence in situ
hybridization (FISH) are the most widely used and have high
reported concordance [9–10]. FISH has been shown to more
accurately select patients than IHC, but is more costly and not
routinely available. The recommended algorithm for HER2
determination in breast cancer is to use IHC initially, using
a semi-quantitative scoring system followed by FISH for 2+
ambiguous samples [11–14].
Observed rates of HER2 overexpression/amplification in
ovarian carcinomas show considerable variation between studies,
ranging from 8% to 66% [15–33]. Single-agent trastuzumab
therapy was associated with a low response rate (7%) in a series of
heavily pretreated patients with ovarian cancer [22], but the
efficacy of trastuzumab in combination with chemotherapy has
not been tested in this setting.
The aim of the current study was to determine the proportion of
patients with advanced ovarian cancer whose tumors were HER2-
positive. This was assessed using conventional slides from both
primary tumors and metastases and applying reference HER2




Three hundred and twenty patients with advanced primary ovarian
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included. Of these, 243 (75.9%) had been enrolled in a larger phase
III GERCOR-AGO-OVAR-9 randomized trial of first-line pacli-
taxel/carboplatin/gemcitabine (TCG) chemotherapy, conducted in
58 centers between July 2002 and April 2004 [ClinicalTrials.gov
Identifier: NCT00052468]. The clinical characteristics of patients
include inthe TCG trial are presented inTable 1. The 77 remaining
patients (56 centers) included in our analysis demonstrated
paclitaxel/carboplatin chemoresistance (defined as progression
duringtherapyorrelapsewithin6 monthsaftercompletingtherapy).
Ethics
The study was approved by the local ethical committee (CCPPRB
number: 02780) and all individual patients gave written informed
consent for biological studies.
HER2 determination by IHC
Formalin-fixed and paraffin-embedded tumors from primary
surgery were obtained retrospectively. Because of previously
reported heterogeneity in HER2 expression in ovarian cancer
[24], in the present study we chose to analyze four blocks
containing tumor: two blocks of primary tumors and two blocks of
chemo-naı ¨ve metastases/peritoneal dissemination (available from
206 patients). Most of the metastases analyzed were peritoneal
dissemination, whereas few corresponded to lymph node sections.
Following deparaffinization and rehydration, the 4 mm sections
were microwave pretreated in pH 6 citrate buffer. Primary
antibody (CB-11, Novocastra, Newcastle-upon-Tyne, UK) diluted
1/800 was incubated for 2 hours. Staining was achieved using
a streptavidin-biotin-peroxidase kit (Abcys, Biospa, Milano, Italy)
including 30-minute incubation for each step. Nuclei were counter-
stained with haematoxylin. HER2 positivity was assessed using Ellis
and Wolff recommendations [14],[25]. A score of 1+ was defined as
barely perceptible membrane staining in more than 10% of cells,
as c o r eo f2 + was defined as weak-to-moderate complete membrane
with staining present inmorethan 10%oftumor cells, and a scoreof
3+ was defined as strong complete membrane staining in more than
10% of tumor cells. We classified 2+ as equivocal and 3+ as positive.
Cytoplasmic staining was considered to be non-specific. For each
case, an external control containing two FISH-positive (2+/3+)
breast cancer samples was used.
HER2 determination by FISH
All samples of 2+/3+ HER2 protein expression and 24 samples with
0/1+ staining score were evaluated by FISH, performed on a single
block in one of the following laboratories, according to local
instutitional procedures: Institut Curie, Paris (PathVysion HER2 kit;
Abbott-Vysis, Desplaines, IL); Centre Jean Perrin, Clermont-Ferrand
(PathVysion HER2 kit; Vysis, IL); Ho ˆtel-Dieu, Paris, (HER2 kit,
DakoCytomation, Glostrup, Denmark). Instructions from the test kit
manufacturers were followed, with slight modifications.
Four mm deparaffinized sections were incubated in pretreatment
buffer at 95uC for 15 minutes, then in proteolytic solution at 37uC
for 5 minutes. Co-denaturation of the probe and DNA of the tissue
section was achieved by incubation at 82uC for 5 minutes using
a HyBrite device (Abbott-Vysis) ; this was followed by a 15-hour
hybridization at 37uC. Post-hybridization washes were performed
accordingtotherespectiveprotocols.Slidesweremounted inDAPI/
antifade and viewed with a fluorescent microscope. Sixty nuclei in
several areas of the section were analyzed, and three representative
imagespercasewerecaptured.Tumorswereclassifiedasamplifiedif
theyshowed a mean of$8 HER2signals,ora HER2/centromere17
ratio .2.2 in samples of fewer than 8 HER2 signals.
Statistics
The study was designed to evaluate HER2 status in a population of
patients with advanced ovarian cancer. HER2 status in primary
tumors and metastases was compared using kappa testing. The
relationship between clinical characteristics of the 243 patients
included in the TCG trial and HER2 status was compared using
chi-square testing. Overall survival (OS) was calculated from the
date of inclusion to death and progression-free survival (PFS) was
calculated from the date of inclusion until progression or last
follow-up examination. Progression was defined as a 20% increase
in the diameter of all measured lesions, appearance of new lesions
and/or doubling from baseline of CA125 tumor marker
concentration. OS and PFS curves were derived from Kaplan-
Meier estimates. A univariate Cox model analysis was performed
to estimate and test the prognostic influence of clinical and
biological variables. In a multivariate analysis, the Cox pro-
portional hazard regression model was applied to determine the
influence of these variables on outcome, adjusted for other
prognostic factors. Hazard ratios (HR) and 95% confidence

















Missing values 1 (0.4)
Grade
Well differentiated (1–2) 97 (39.9)
Poorly differentiated (3–4) 143 (58.9)








Missing values 37 (15.2)
Residual tumour after first laparotomy
Residual disease#1cm 115 (47.3)
Residual disease .1cm 128 (52.7)
WHO: World Health Organization; FIGO: International Federation of Gynecology
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PLoS ONE | www.plosone.org 2 November 2007 | Issue 11 | e1138intervals (CI) were determined. The influence of HER2 status in
drug-resistant ovarian cancer was assessed in a subset of 109
patients with FIGO stage IIIc -IV disease and sub-optimal surgery.
The resistant group was defined as presenting a first progression
during or within 6 months following the end of treatment. The
sensitive group was defined as non-progressive patients within the
year after the end of treatment. HER2 status between resistant and
sensitive groups was evaluated using exact Fisher testing. P values
#0.05 were considered significant. All analyses were performed
using SPlus software (Insightful, Seattle, WA).
RESULTS
HER2 overexpression
Of the 320 tumors analyzed, HER2 3+ staining was observed in 15
samples (4.7%) and 2+ in 26 samples (8.1%) (Figure 1). HER2
expression of 0 or 1+ was detected in the 279 remaining samples
(87.2%). One-third of tumors showed some intracytoplasmic
staining, considered as non-specific (data not shown). Among the
41 samples with 2+/3+ staining, 19 (46.3%) were heterogeneous
and the same pattern was seen in the metastatic samples.
Of the 206 patients from whom both primary tumor and distant
metastatic samples were available, there was concordance between
primary tumor and metastases in 197 samples (95.6%; 179
negative and 18 positive). No statistical difference between HER2
overexpression in primary tumors and corresponding metastases
could be identified by kappa testing. In nine samples, 2+/3+ HER2
staining was found exclusively in either primary tumor (five
samples) or metastases (four samples). Three of these nine samples
showed 3+ overexpression and were amplified. The six remaining
samples showed 2+ expression and one of these showed HER2
gene amplification by FISH.
HER2 gene amplification
Sixty-five samples were analyzed by FISH for HER2 amplification,
including all of the 26 equivocal (2+) tumors, the 15 positive (3+)
tumors, and 24 samples showing 1+ or cytoplasmic staining. Three
samples (two with 2+ and one with 3+ staining) were not evaluable
because of DNA alteration by fixation, despite two attempts
conducted in two laboratories. Thus a total of 62 samples were
evaluated by FISH (Figure 2). In total 21 patients showed HER2
positive status (all of the samples with IHC 3+ score and 6 of 24
samples with IHC 2+ score validated by FISH). None of the 24
samples with 1+ or cytoplasmic positivity was amplified for HER2.
In the heterogeneous samples, HER2 overexpression and
amplification were found in the same tumor areas. Eighteen of
21 samples with HER2 amplification showed more than 8 copies
per tumor nucleus with large clusters, suggesting homogeneous
staining regions. The three remaining samples showed amplifica-
tion with 8–10 copies per tumor nucleus, and a significant HER2/
centromere 17 ratio.
Relationship between biological markers and other
prognostic variables
No relationship between HER2 status and other prognostic factors
(tumor stage, histological type, grade, ascites, debulking status, age
and performance status) was found.
Survival analysis
Median follow-up was 24.9 months (95% CI: 23.4–26.3). At the time
of our analysis (July 2006), disease progression had occurred in 150
(61.7%) patients and 66 (27.2%) had died. Median PFS duration was
17.7 months(95%CI:15.3–20.6).MedianOShadnotbeenreached.
Among the 41 patients whose tumor was 2+/3+ by IHC, disease
progressedin18(43.9%)andtherewereseven(17.1%)deaths,whilein
the group of 16 patients with HER2 amplification, disease progressed
in 12 (75%) and there were four (25%) deaths (Figure 3).
Univariate analysis
Univariate analysis of the potential prognostic impact of clinical
and histopathological parameters identified performance status 1
or 2, tumor stage, ascites and residual tumor after first laparotomy
as significantly associated with shorter OS and PFS (Table 2). The
association between age $ 60 years and poorer OS was borderline
significant. HER2 status (evaluated by either IHC or FISH) was
not of prognostic value in terms of OS and PFS.
Multivariate analysis
Age, performance status, FIGO stage, ascites, residual tumor after
first laparotomy and HER2 amplification/overexpression status
were considered. Only the presence of ascites was retained as an
independent prognostic factor of both shorter PFS (P=0.037) and
OS (P=0.016) (Table 3). High FIGO stage was also retained as
a prognostic factor for PFS (P=0.00041) alone. HER2 status had
no significant impact.
Chemoresistance and HER2 status
From the cohort of patients included in the TCG trial, a subset of
109 patients with FIGO stage IIIc/IV primary tumor and sub-
Figure 1. Immunohistochemistry labeling results. A. 2+ score: weak-
to-moderate complete membrane staining in more than 10% of tumor
cells (objX40). B. 3+ score: strong complete membrane staining in more
than 10% of tumour cells (objX40). C. Heterogeneous staining of
a primary ovarian tumour (objX20). D: Heterogeneous staining of
a metastasis (objX20) E. FISH: heterogeneous amplification of HER2 in
a tumor showing a cluster of tumor cells with amplification (white
arrow, left part) and a cluster of non amplified tumor cells (orange
arrow, right part). F: Clusters of red spots (HER2 amplification) together
with two green spots (centromere 17).
doi:10.1371/journal.pone.0001138.g001
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PLoS ONE | www.plosone.org 3 November 2007 | Issue 11 | e1138optimal surgery was selected for analysis. Based on follow-up, 46
patients were considered as chemoresistant, 36 as chemosensitive,
and 27 could not be classified in one of the two groups. HER2
status was not significantly linked to chemoresistant status.
DISCUSSION
In this study, we screened 320 advanced ovarian cancers for HER2
status. To our knowledge, this is the first large multicentric study
investigating both primary tumor and metastases on conventional
slides by IHC and FISH techniques. Positive HER2 status was
found in 6.6% (21 of 320) of the tumor samples. The rate of HER2
positivity varies in the literature from 8% to 66% [15–33]
(Figure 4). There are several possible explanations for the wide
variation and the relatively low rate of HER2 positivity reported in
our series, including the different detection methods used (IHC,
FISH and chromogenic in situ hybridization), different sources of
material (blocks of tumors and tissue microarray), and variations in
IHC assay techniques (CB-11, HercepTest or a non-commercial
antibody); in addition, variance in staining protocols and sub-
jective interpretation of sample stains makes direct comparison of
studies difficult. The present study has the advantage of being
based on a large, prospective, multicenter trial, with extensive
tumor sampling (four conventional slides of tumor/metastases
when available). Moreover, all of the positive/doubtful samples
(IHC 1+,2 +,3 + and those with cytoplasmic staining) were
analyzed by FISH. The rate of HER2 protein overexpression (2+/
3+ by IHC) was 13% in the present series, whereas it varied from
1.9% to 35% in previous reports. We used the CB-11 monoclonal
antibody, which has been shown to be more accurate than
HercepTest, the other widely used, Food and Drug Administration
(FDA)-approved antibody [12], [34], and to show better
concordance with FISH ([11], [35]). To our knowledge, no
cross-reactivity with other EGFR family protein has been reported
using this antibody [31]. We adapted our IHC assay according to
Couturier et al. [36] with a dilution of the primary antibody (1/
800), since this procedure has shown a complete concordance with
gene amplification assessed by FISH. Our results confirm the good
concordance between IHC and FISH analyses in ovarian cancers
because all the samples showing 1+ staining or cytoplasmic
staining were not amplified, thus excluding the hypothesis of
possible false negatives. It is worth noting that HER2 testing
procedures have evolved with time, resulting in a more consistent
rate of positive cases (11–16%) in most of the recent studies.
Compared with the 20–30% rate of HER2 positivity observed in
breast cancers [34], [37], the rate in ovarian cancer is lower and
intratumoral heterogeneity is frequently detected. The good
concordance between HER2 status in primary tumor and
corresponding distant locations suggests that HER2 clonal
selection occurs before tumor dissemination. It is worth noting
that some tumors showed the same heterogeneous pattern in both
primary and distant locations with adjacent positive and negative
areas, detected by both IHC and FISH methods.
We observed a good correlation between IHC and FISH results
forno/weak(0/1+)andstrong(3+)IHCscores,whereasonly25%of
the IHC 2+ samples were found to be amplified by FISH testing. A
similar rate has been reported in breast cancer [10], [38]. Moreover,
it has been shown that among 2+ IHC false positive cases, none
overexpressed HER2 mRNA as mesured by in situ hybridization
[12]. Our results show that the decision algorithm currently used in
breast cancers (IHC as a screening test, with equivocal results
confirmed by FISH) is appropriate in ovarian cancers. HER2
amplification/overexpression is associated with poor prognosis in
several cancer types, and its prognostic value in ovarian cancer has
been reviewed recently by Serrano-Olvera et al. [39]. An adverse
prognostic impact of HER2 overexpression and/or amplification has
been shown in most of the published series [3], [16–18], [23], [27],
[28], [30], [32], [40], including one reported by our group [24]. In
the present study, we did not identify any prognostic value of HER2
status. In contrast to our previous study [24], patients in the present
series received paclitaxel-based chemotherapy, raising the question
of a possible interaction between HER2 positivity and drug
sensitivity. The clinical impact of HER2 status on the response to
paclitaxel has been suggested, but a significant association has not
been shown [41–42]. Interestingly, in vitro studies in the SK-OV-3
ovarian cancer cell line showed that sensitivity to paclitaxel
dramatically increased in cells expressing high levels of HER2 [43].
Since HER2-positive cells are likely dividing rapidly, they may be
more sensitive to paclitaxel-based chemotherapy. Altogether, these
results suggest that paclitaxel may overcome the poor prognosis
associated with HER2 positivity targeting dividing cells.
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Figure 2. HER2 gene amplification repartition according to HER2
protein status. Perfect concordance in protein expression and gene
amplification has been observed for samples with 3+ or 0/1+ IHC
staining. In our study, 25% of equivocal samples (IHC 2+ staining) were
amplified for HER2 gene. Based on the HER2 reference scoring
algorithm, 21 samples were considered as positive (15 scored 3+ by
IHC and 6 scored 2+ validated by FISH). Three samples could not be
compared by FISH due to fixation (one 3+ and two 2+ IHC scored).
IHC=immunohistochemistry; FISH=fluorescence in situ hybridization.
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Table 2. Univariate analysis for progression-free survival and overall survival of biological and clinical parameters
..................................................................................................................................................
Factor Overall survival Progression free survival
HR [95%CI] P-value HR [95%CI] P-value
HER2 1.29 [0.37; 2.8] 0.58 1.4 [0.79; 2.59] 0.23
Positive vs. negative (IHC+FISH)
HER2 0.809 [0.34; 1.87] 0.6 0.805 [0.49; 1.32] 0.39
IHC 2+/3+ vs 0/1+
HER2 0.948 [0.51; 1.74] 0.86 0.809 [0.54; 1.19] 0.29
IHC 1+/2+/3+ vs 0
Age 1.60 [0.97; 2.63] 0.057 1.22 [0.89; 1.7] 0.2
$60 years vs ,60 years
Performance status 2.75 [1.54; 4.88] 0.00059* 1.62 [1.15; 2.26] 0.005*
1/2 vs 0
Tumor stage 6.81 [1.66; 27.86] 0.0076* 4.37 [2.3; 8.38] ,0.00001*
III-VI vs I-II
Ascites 3.07 [1.62; 5.78] 0.00048* 2.04 [1.41; 2.92] 0.00013*
Presence vs absence
Residual tumour after first laparotomy 2.29 [1.33; 3.93] 0.0018* 2.3 [1.64; 3.22] ,0.00001*
.1c mv s#1cm
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Table 3. Multivariate analysis of clinical parameters for progression-free survival and overall survival
..................................................................................................................................................
Factor Overall survival Progression free survival
HR [95%CI] P-value HR [95%CI] P-value
HER2 1.44 [0.51; 4.00] 0.49 1.67 [0.86; 3.22] 0.12000
Positive vs negative(IHC+FISH)
Age 1.28 [0.73; 2.24] 0.380 1.06 [0.74; 1.52] 0.74
$60 years vs ,60 years
Performance status 1.65 [0.86; 3.16] 0.12 1.26 [0.85; 1.85] 0.23000
1/2 vs 0
Tumor stage 6.75 [0.17; 254.6] 0.064 3.96 [1.84; 8.4] 0.00041*
III-IV vs I-II
Ascites 2.23 [0.79; 6,21] 0.016* 1.51 [1.02; 2.22] 0.037*
Presence vs absence
Residual tumor after first laparotomy 1.16 [0.44; 3.03] 0.62 1.26 [0.84; 1.86] 0.26
.1c mv s#1c m






































































Figure 4. HER2 in major published studies. A. Overexpression Review of selected articles evaluating HER2 protein expression in large series of
patients (including more than 50 tumour samples) published in international journals after 1994. Boxes represent % of HER2 overexpression (scored
as 2+ or 3+) and error bars show 62 standard errors for each study. B. IHC and FISH status Review of selected articles evaluating HER2 gene
amplification (FISH or CISH) and/or HER2 protein expression in large series of patients (including more than 50 tumour samples) published in
international journals after 1994.In situ hybridisation represents FISH (fluorescence in situ hybridisation) and CISH (chromogenic In situ hybridisation)
results. Mean HER2 overexpression/amplification across studies is represented; IHC=Immunohistochemistry.
doi:10.1371/journal.pone.0001138.g004
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